{"id":25351,"date":"2022-11-10T10:38:58","date_gmt":"2022-11-10T09:38:58","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=25351"},"modified":"2022-11-22T12:38:40","modified_gmt":"2022-11-22T11:38:40","slug":"ip-due-diligence-und-pharma-transkript-4-2022","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/jp\/publications\/ip-due-diligence-und-pharma-transkript-4-2022\/","title":{"rendered":"IP Due Diligence und Pharma, |transkript 4-2022 im November &#8211; Spezial: &#8220;Patente \/ M&#038;A \/ Lizenzierung&#8221;"},"content":{"rendered":"\n<p>Market leaders in the life sciences are interested in acquiring start-ups in order to acquire a new technology as soon as their investment risk can be better foreseen. In order to minimise the associated risks, a precise IP due diligence is required on the acquirer&#8217;s side. In this article, <a href=\"https:\/\/www.maiwald.eu\/jp\/team\/marco-stief\/\">Dr Marco Stief<\/a> tries to summarise the most important issues to consider in the article &#8220;IP Due Diligence and Pharma&#8221; for Transkript.&nbsp;&nbsp;<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-25351","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/25351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":13,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/25351\/revisions"}],"predecessor-version":[{"id":25810,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/25351\/revisions\/25810"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/media?parent=25351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}